XML 65 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Financial Data for the Company’s Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Research & development expense – clinical asset development $ 1,309 $ 128
General and administrative expenses – salaries, payroll and stock-based compensation 2,700 2,827
Loss from segment operations (4,009) (2,955)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Research & development expense – related parties 1,120
General and administrative expenses – other 703 949
Loss from segment operations 4,009 2,955
Operating Segments [Member] | Clinical Asset Development [Member]    
Segment Reporting Information [Line Items]    
Research & development expense – clinical asset development 189 128
Operating Segments [Member] | Legal And Professional Fees [Member]    
Segment Reporting Information [Line Items]    
General and administrative expenses – salaries, payroll and stock-based compensation 760 245
Operating Segments [Member] | Accounting And Audit Fees [Member]    
Segment Reporting Information [Line Items]    
General and administrative expenses – salaries, payroll and stock-based compensation 544 647
Operating Segments [Member] | Salaries Payroll And Stock Based Compensation [Member]    
Segment Reporting Information [Line Items]    
General and administrative expenses – salaries, payroll and stock-based compensation $ 693 $ 986